---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-107438"
form_type: "8-K"
ticker: "REPL"
cik: "0001737953"
company_name: "Replimune Group, Inc."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:51:33.714283+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Replimune reports Q2 net loss $83.1M; FDA accepts RP1 BLA resubmission with PDUFA April 10, 2026

## Summary
- Cash, equivalents and investments $323.6M at Sep 30, 2025, down from $483.8M at Mar 31, 2025.
- R&D expenses $57.9M vs $43.4M YoY; S,G&A $26.4M vs $15.5M YoY.
- Net loss $83.1M vs $53.1M in prior year quarter.
- FDA accepted BLA resubmission for RP1 in advanced melanoma; PDUFA target action date April 10, 2026.
- Phase 3 IGNYTE-3 trial enrolling ~400 patients; REVEAL Phase 2/3 for RP2 in uveal melanoma enrolling.

## SEC filing metadata
- accession: 0001104659-25-107438
- form_type: 8-K
- ticker: REPL
- cik: 0001737953
- company_name: Replimune Group, Inc.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737953/000110465925107438/0001104659-25-107438-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737953/000110465925107438/tm2530417d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-107438
- JSON: https://secwatch.observer/filing/0001104659-25-107438.json
- Plain text: https://secwatch.observer/filing/0001104659-25-107438.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.